The Goldman Sachs Group Begins Coverage on Immunome (NASDAQ:IMNM)

Research analysts at The Goldman Sachs Group began coverage on shares of Immunome (NASDAQ:IMNM) in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $26.00 price target on the stock. The Goldman Sachs Group’s target price indicates a potential upside of 146.21% from the stock’s current price.

A number of other research firms also recently commented on IMNM. Wedbush restated an “outperform” rating and set a $21.00 price target on shares of Immunome in a research report on Thursday, September 18th. Craig Hallum initiated coverage on shares of Immunome in a research report on Friday, September 5th. They set a “buy” rating and a $26.00 price target on the stock. JPMorgan Chase & Co. dropped their price target on shares of Immunome from $23.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. Guggenheim reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Immunome in a research note on Monday, August 25th. Finally, Evercore ISI initiated coverage on shares of Immunome in a research note on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $23.20.

Immunome Trading Up 8.1%

IMNM stock opened at $10.56 on Monday. Immunome has a 52 week low of $5.15 and a 52 week high of $15.20. The company has a market capitalization of $919.14 million, a price-to-earnings ratio of -3.43 and a beta of 1.92. The firm’s 50-day moving average is $10.07 and its two-hundred day moving average is $8.85.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The company had revenue of $4.02 million for the quarter, compared to the consensus estimate of $1.03 million. On average, equities research analysts predict that Immunome will post -2.21 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Immunome by 2,822.9% in the first quarter. GAMMA Investing LLC now owns 6,138 shares of the company’s stock worth $410,000 after acquiring an additional 5,928 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares in the last quarter. Brighton Jones LLC purchased a new position in shares of Immunome in the second quarter worth approximately $98,000. Finally, Whalen Wealth Management Inc. purchased a new position in shares of Immunome in the second quarter worth approximately $128,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.